KEYTRUDA + WELIREG PDUFA Date (Merck)

Name: FDA PDUFA Decision: KEYTRUDA + WELIREG
Start: 2026-06-19

FDA PDUFA decision date for KEYTRUDA + WELIREG is June 19, 2026. Developed by Merck. Indication: Clear cell renal cell carcinoma (adjuvant setting). Current status: Approved.

Indication

Clear cell renal cell carcinoma (adjuvant setting)

Regulatory details

Company: Merck
Therapeutic area: Oncology
Application type: sNDA
Review type: Priority
PDUFA date: 2026-06-19
Outcome: Approved

KEYTRUDA + WELIREG PDUFA Date — Merck